Biotechnology company Biogen is buying the gene therapy developer for about $877 million in an all-cash deal. Enbridge Inc., down $2.19 to $35.06.
News
- Nightstar Therapeutics soars while Children's Place tumbles
- Texas Biomed scientists developing new vaccine strategy for tuberculosis
San Antonio, Texas (March 4, 2019) - For years, scientists have been trying to come up with a better way to protect people against tuberculosis, the ...
- Hope for US-China deal pushes stocks higher
BIOTECH BUMP: Gene therapy developer Nightstar Therapeutics surged 66 percent after biotech giant Biogen offered to buy it for $877 million in ...
- PUMA BIOTECHNOLOGY, INC. filed 10-K on Mar 01
PUMA BIOTECHNOLOGY, INC. filed 10-K with SEC. Read 's full filing at 000156459019005830. The aggregate market value of voting stock held by ...
- People: Strategic Staffing Solutions, Pipeline Talent Solutions, ExecThread, PTS Advance, Beacon ...
... second-largest service offering; he is based out of its San Antonio, Texas ... appointed Jayne Gill as managing director in its life science division.